Acadia Pharmaceuticals announces FDA approval of Daybue Stix for oral solution

Acadia Pharmaceuticals (ACAD) announced that the FDA has approved Daybue Stix for oral solution, a dye- and preservative-free powder formulation of trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. The new formulation is expected to deliver the same efficacy and safety profile of Daybue oral solution, while offering children and adults living with Rett syndrome new flexibility and choice regarding the dose volume and taste of their Daybue treatment.